PMID- 10395660
OWN - NLM
STAT- MEDLINE
DCOM- 19990729
LR  - 20191210
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 163
IP  - 2
DP  - 1999 Jul 15
TI  - Induction of antitumor immunity with dendritic cells transduced with adenovirus 
      vector-encoding endogenous tumor-associated antigens.
PG  - 699-707
AB  - Dendritic cells (DCs) are professional Ag-presenting cells that are being 
      considered as potential immunotherapeutic agents to promote host immune responses 
      against tumor Ags. In this study, recombinant adenovirus (Ad) vectors encoding 
      melanoma-associated Ags were used to transduce murine DCs, which were then tested 
      for their ability to activate CTL and induce protective immunity against B16 
      melanoma tumor cells. Immunization of C57BL/6 mice with DCs transduced with Ad 
      vector encoding the hugp100 melanoma Ag (Ad2/hugp100) elicited the development of 
      gp100-specific CTLs capable of lysing syngeneic fibroblasts transduced with 
      Ad2/hugp100, as well as B16 cells expressing endogenous murine gp100. The 
      induction of gp100-specific CTLs was associated with long term protection against 
      lethal s.c. challenge with B16 cells. It was also possible to induce effective 
      immunity against a murine melanoma self Ag, tyrosinase-related protein-2, using 
      DCs transduced with Ad vector encoding the Ag. The level of antitumor protection 
      achieved was dependent on the dose of DCs and required CD4+ T cell activity. 
      Importantly, immunization with Ad vector-transduced DCs was not impaired in mice 
      that had been preimmunized against Ad to mimic the immune status of the general 
      human population. Finally, DC-based immunization also afforded partial protection 
      against established B16 tumor cells, and the inhibition of tumor growth was 
      improved by simultaneous immunization against two melanoma-associated Ags as 
      opposed to either one alone. Taken together, these results support the concept of 
      cancer immunotherapy using DCs transduced with Ad vectors encoding 
      tumor-associated Ags.
FAU - Kaplan, J M
AU  - Kaplan JM
AD  - Genzyme Corporation, Genzyme Molecular Oncology, Framingham, MA 01701, USA. 
      jkaplan@genzyme.com
FAU - Yu, Q
AU  - Yu Q
FAU - Piraino, S T
AU  - Piraino ST
FAU - Pennington, S E
AU  - Pennington SE
FAU - Shankara, S
AU  - Shankara S
FAU - Woodworth, L A
AU  - Woodworth LA
FAU - Roberts, B L
AU  - Roberts BL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PMEL protein, human)
RN  - 0 (Pmel protein, mouse)
RN  - 0 (gp100 Melanoma Antigen)
SB  - IM
MH  - Adenoviridae/genetics/*immunology
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - Bone Marrow Cells/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Dendritic Cells/immunology/*transplantation/virology
MH  - Female
MH  - Genetic Vectors/immunology
MH  - Humans
MH  - Immunotherapy, Active
MH  - Immunotherapy, Adoptive/methods
MH  - Melanoma, Experimental/*immunology/*therapy
MH  - Melanoma-Specific Antigens
MH  - Membrane Glycoproteins/genetics/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasm Proteins/genetics/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Transfection/*immunology
MH  - gp100 Melanoma Antigen
EDAT- 1999/07/08 00:00
MHDA- 1999/07/08 00:01
CRDT- 1999/07/08 00:00
PHST- 1999/07/08 00:00 [pubmed]
PHST- 1999/07/08 00:01 [medline]
PHST- 1999/07/08 00:00 [entrez]
AID - ji_v163n2p699 [pii]
PST - ppublish
SO  - J Immunol. 1999 Jul 15;163(2):699-707.